These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 24879506)
21. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984 [TBL] [Abstract][Full Text] [Related]
22. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors. Case A; Ni J; Yeh LA; Stein RL Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743 [TBL] [Abstract][Full Text] [Related]
23. Synthesis of novel pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives and their inhibition against growth of A549 and H322 lung cancer cells. Zheng LW; Shao JH; Zhao BX; Miao JY Bioorg Med Chem Lett; 2011 Jul; 21(13):3909-13. PubMed ID: 21640587 [TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of Two Series of Novel A-Ring Fused Steroidal Pyrazines as Potential Anticancer Agents. Wang S; Yuan X; Qian H; Li N; Wang J Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121303 [TBL] [Abstract][Full Text] [Related]
26. Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1. French KJ; Zhuang Y; Schrecengost RS; Copper JE; Xia Z; Smith CD J Pharmacol Exp Ther; 2004 Apr; 309(1):340-7. PubMed ID: 14724220 [TBL] [Abstract][Full Text] [Related]
27. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners. Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647 [TBL] [Abstract][Full Text] [Related]
28. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models. Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445 [TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines. Kékesi L; Sipos A; Németh G; Pató J; Breza N; Baska F; Őrfi L; Kéri G Bioorg Med Chem Lett; 2013 Nov; 23(22):6152-5. PubMed ID: 24095095 [TBL] [Abstract][Full Text] [Related]
30. Irreversible inhibitors of tissue transglutaminase. Keillor JW; Chabot N; Roy I; Mulani A; Leogane O; Pardin C Adv Enzymol Relat Areas Mol Biol; 2011; 78():415-47. PubMed ID: 22220480 [No Abstract] [Full Text] [Related]
31. Potential of transglutaminase 2 as a therapeutic target. Caccamo D; Currò M; Ientile R Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177 [TBL] [Abstract][Full Text] [Related]
32. Studies on pyrazine derivatives. XLVII. Synthesis and antibacterial activity of novel pyrazine derivatives with amidoxime moiety. Gobis K; Foks H; Kedzia A; Wierzchowska M; Kwapisz E; Zwolska Z; Augustynowicz-Kopeć E Acta Pol Pharm; 2006; 63(1):39-45. PubMed ID: 17515328 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides. Xu S; Sun C; Chen C; Zheng P; Zhou Y; Zhou H; Zhu W Molecules; 2017 Feb; 22(2):. PubMed ID: 28218676 [TBL] [Abstract][Full Text] [Related]
34. [Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction]. Kékesi L; Sipos A; Németh G; Dancsó A; Illyés E; Boros S; Breza N; Nemes Z; Hegymegi-Barakonyi B; Pató J; Greff Z; Kéri G; Őrfi L Acta Pharm Hung; 2014; 84(3):91-104. PubMed ID: 25470976 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological assay in vitro and molecular docking studies of new imidazopyrazinone derivatives as potential dipeptidyl peptidase IV inhibitors. Zhu Y; Xia S; Zhu M; Yi W; Cheng J; Song G; Li Z; Lu P Eur J Med Chem; 2010 Nov; 45(11):4953-62. PubMed ID: 20800322 [TBL] [Abstract][Full Text] [Related]
36. Calreticulin down-regulates both GTP binding and transglutaminase activities of transglutaminase II. Feng JF; Readon M; Yadav SP; Im MJ Biochemistry; 1999 Aug; 38(33):10743-9. PubMed ID: 10451369 [TBL] [Abstract][Full Text] [Related]
37. N Wodtke R; Hauser C; Ruiz-Gómez G; Jäckel E; Bauer D; Lohse M; Wong A; Pufe J; Ludwig FA; Fischer S; Hauser S; Greif D; Pisabarro MT; Pietzsch J; Pietsch M; Löser R J Med Chem; 2018 May; 61(10):4528-4560. PubMed ID: 29664627 [TBL] [Abstract][Full Text] [Related]
38. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696 [TBL] [Abstract][Full Text] [Related]
39. Synthesis of potent water-soluble tissue transglutaminase inhibitors. Griffin M; Mongeot A; Collighan R; Saint RE; Jones RA; Coutts IG; Rathbone DL Bioorg Med Chem Lett; 2008 Oct; 18(20):5559-62. PubMed ID: 18812257 [TBL] [Abstract][Full Text] [Related]
40. QSAR studies on imidazopyrazine derivatives as Aurora A kinase inhibitors. Leng Y; Lu T; Yuan HL; Liu HC; Lu S; Zhang WW; Jiang YL; Chen YD SAR QSAR Environ Res; 2012 Oct; 23(7-8):705-30. PubMed ID: 22971111 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]